The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
1. CannEpil® is a Phytocannabinoid derived IMP used as a treatment for refractory epilepsy
* Available to prescribe in Australia and UK as an Investigational Medicinal Product through early patient access schemes
*Estimated yearly average treatment costs per patient: A$10,000 – A$14,000
Target Market:
• Over 1,900,000 people have epilepsy in Europe (over 480,000 epilepsy patients in the UK)
• Over 200,000 epilepsy patients in Australia
• Approximately 25% of people with epilepsy have a drug-resistant (DRA) form
• Estimated population at the launch of marketing authorization is over 200,000 people with DRA (in Europe and Australia)
• Expected time to marketing authorization 4 years
The global epilepsy market is expected to be ~A$12.9bn by 2023
************************
2.CogniCann® is MGC Pharma’s second Phytocannabinoid derived IMP designed to improve dementia and Alzheimer’s disease patients quality of life
*Available to prescribe in Australia as an Investigational Medicinal Product through Early Patient Access Scheme
*Estimated yearly average treatment costs per patient: A$7,800
Target Market:
• Over 690,000 people with mild dementia in Europe (over 200,000 mild dementia patients in the UK)
• Over 135,000 mild dementia patients in Australia
• Total estimated with mild dementia population 950,000 at marketing authorization launch (in Europe and Australia)
• Expected time to marketing authorization 5 years
The global dementia medication market is expected to exceed ~A$40bn by 2026
If anybody uses T212 it shows AIM. but that is not correct. it should be on the main market. I have sent an email to them and they confirm MGC is on the main market and they try to fix it as soon as possible.
@Pokerchps
Yes sure, but on the Onassis Holdings Corp they advertise for wholesaling but on this website, they sell as individuals and the website has been set up in 2020 that's why I'm not sure.
and this is for everyone here:
ArtemiC™ is on the market for $79 but I'm not sure if this is a new website or an old one because is not working properly.
worth to lookup
https://www.corona-blox.com/
@ncar16
This is a contract between MGC Pharma and Onassis Holdings Corp ( Desember 2020 )
https://www.proactiveinvestors.com.au/companies/news/935429/mgc-pharmaceuticals-progresses-sale-of-nutraceuticals-subsidiary-to-us-based-onassis-holdings-corp-935429.html
@BeffJezos
I hope this statement gives you some clue. This is from December 2020
• Strong quarter delivered with global MGC Pharma product sales generating revenue of
$456,000 from 2,900 units of products sold. This represents an increase of 67% growth from
the previous quarter.
• Significant operational and commercial progress delivered across all pharma operations
pushing the Company towards its goal of achieving monthly cashflow breakeven by end 1H
2021 from ~ 5,000 units sold per month.
• Acquisition of Medicinal Cannabis Clinics completed, with over 300 patient consults
conducted since completion on the 23rd of November. Alongside the increased revenue
generated from consults, the acquisition brings distribution that provides higher import and
export capacity with significantly higher profit margins while maintaining a competitive product
prices.
• Results from an ongoing study into the treatment of glioblastoma show MXC’s proprietary
formulation, CBG, impairs the major hallmarks of glioblastoma progression.
• Launch of CannEpil® app which provides access to the international library of Cannabinoids as
part of its ongoing research with RMIT.
• The sale of MGC Nutraceuticals significantly advanced as both the Company and Onassis have
submitted the required documentation to the US SEC.
Plus the new contract with Swiss PharmaCan AG and hopefully the new future contracts.
ONASIS company starts the marketing for ArtemiC™ for a minimum order of 1000 units up to 250.000 units in the USA and Central America
Upcoming events on MGC PHARMACEUTICALS LIMITED
03/03/21 Interim 2021 Earnings Release (Projected)
08/24/21 FY 2021 Earnings Release (Projected)
03/02/22 Interim 2022 Earnings Release (Projected)
03/01/23 Interim 2023 Earnings Release (Projected)
in the future as part of a Phase III study where the Company would look to develop ArtemiC™ as a pharmaceutical product and future development as an Investigational Medicinal Product (IMP).
The Phase III Clinical trial is anticipated to be an international multicentre study with up to 250 patients and expand its research to encompass a wide range of inflammatory indications for the use of ArtemiC™ as a treatment.
Upon completion of a successful Phase III Clinical Trial the Company will seek registration of ArtemiC™ and commence production and sale as a supplement, through its existing production facilities and distribution networks.
Successful results of Phase III will lead for a pre-IND meeting with FDA in order to initiate the registration process for ArtemiC™ as an IMP.
I'm not an expert on this matter.
but with my research on this drag and info from the company, ArtemiC is a food supplement, and the company mention they pass phases 1 and 2 with %100 results and they follow all FDA rolls. I think you need to do some more research on that.
I would trust the MGC because they are %100 experts on that.
roby zomer (@ZomerRoby) Tweeted: Coming soon to support your daily immune system work. https://t.co/j3Fl3zBPGg https://twitter.com/ZomerRoby/status/1363920995921186823?s=20
don't worry mate :)
Regulatory approvals to commence the Phase III Clinical Trial will be progressed with Anvisa (Brazilian medical Authority), EU Novel Food authority, and submissions are expected to be made in the first quarter of 2021. The Company plans to develop and commence a Phase III Clinical Trial in the first half of 2021.
So I guess sometimes around June
Goodmorning Nige7
Please read this statement it explains exactly the future of progress for ArtemiC™
Next steps
Following the successful Phase II results, further development for ArtemiC™ will include immediate evaluation of a Phase III clinical study on COVID-19 and flu patients, and production in MGC EU GMP facilities as IMP under a new brand name. In addition, different indications related to inflammation and cytokine storm, will be considered as future development goals and include a wide range of diseases related to cytokine storm such as autoimmune diseases, inflammatory GI diseases, flu and chemotherapy patients.
The Company is in a strong position to respond to a significant potential increase in the demand for ArtemiC™ in the immediate future as a supplement, and in the future as part of a Phase III study where the Company would look to develop ArtemiC™ as a pharmaceutical product and future development as an Investigational Medicinal Product (IMP).
Regulatory approvals to commence the Phase III Clinical Trial will be progressed with Anvisa (Brazilian medical Authority), EU Novel Food authority and submissions are expected to be made in first quarter of 2021. The Company plans to develop and commence a Phase III Clinical Trial in the first half of 2021. The Phase III Clinical trial is anticipated to be an international multicentre study with up to 250 patients and expand its research to encompass a wide range of inflammatory indications for the use of ArtemiC™ as a treatment. These indications are related to cytokines storm as autoimmune diseases (rheumatoid arthritis, lupus), flu, chemotherapy patients and IBD could benefit from the mechanism of action ArtemiC™, demonstrated in preclinical and clinical trials.
Upon completion of a successful Phase III Clinical Trial the Company will seek registration of ArtemiC™ and commence production and sale as a supplement, through its existing production facilities and distribution networks.
Successful results of Phase III will lead for a pre-IND meeting with FDA in order to initiate the registration process for ArtemiC™ as an IMP.
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “The results we have seen from ArtemiC™ to date provide a transformational opportunity for the Company. The safety and efficacy demonstrated on COVID-19 patients has now opened the opportunity for a whole range of other indications related to cytokine storm. The Company will now look to progress the immediate opportunities for ArtemiC™ while continuing to pursue further clinical developments.”
Agreed Bushmaster, as I believe each of these white label companies can turn to 100 new brands.
We just need to wait for them to start doing their marketing and get lots of brands to come on board for ArtemiC™.
A very clever move from MGC and don't forget soon as MGC passed Phase III clinical and get the FDA approval this thing would go huge.
@Bushmaster
I did some research on those companies that have been mention in RNS.
So from RNS I can see MGC sign the contract with Swiss PharmaCan AG which you maintain some details about them.
Swiss PharmaCan AG ( white Label company ) / ( SPC to distribute as a food supplement worldwide )
They sell their products in two ways:
1. CREATE YOUR OWN BRAND
BRING THE FUTURE OF NUTRACEUTICALS TO YOUR OWN BUSINESS
Swiss PharmaCan offers you the opportunity to innovate and grow your business in ways you never thought possible. Explore the possibilities through performance, formulation, and packaging.
2. CREATE YOUR OWN FORMULATION
CREATE YOUR OWN BLEND FROM OUR RANGE OF PRODUCTS ENHANCE YOUR OWN COMPOUND
Discover the possibilities: your own, exclusive formulation using our range of products. Alternatively, find out what we can achieve with your current compound.
now we know Swiss PharmaCan AG has signed the contract with Relay Medical Corp and Glow LifeTech Ltd another two white label company ( for exclusive North American and Caribbean sales and distribution ) interesting things about Relay Medical Corp and Glow LifeTech Ltd is :
February 9, 2021 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, is pleased to announce that it has committed to participate in the RTO financing of Glow LifeTech (“Glow”), a privately held Canadian-based biotechnology company in which Relay currently holds a significant equity interest.
and last company is ONASIS Holding Corp another white label company ( as a master distributor in the USA and Central America )
The info I find about them is they use to be Onassis Mining Group, Inc but they change their name in 2019 to ONASIS Holding Corp, and they doing white label for food supplements. I could not find any useful info on them website.
So you think ArtemiC™ Support going to bring extra revenue for the next 3 years with this contract.
at the moment we know the price of 10.000 units of ArtemiC™ Rescue in this contract is $850.000
that would be nice to see the price of 10.000 units of ArtemiC™ Support.
that would change the revenue of the company massively.
Hi guys,
In the RNS company mention below statement:
MGC Pharma will also produce and provide an additional supplement called ArtemiC™ Support which is specifically designed for daily consumption to support and maintain the strength of the human immune system.
So my question is:
is MGC going to charge Swiss Pharma extra to provide the ArtemiC™ Support or not?
For example:
10.000 units of ArtemiC™ Rescue and 10.000 units of ArtemiC™ Support for $850.000
or
10.000 units of ArtemiC™ Rescue for $850.000 and 10.000 units of ArtemiC™ Support for a different value.
I have sent an email to the company to find out but no response.
So what your thought on that?
oh, that is interesting because I'm using T212, in the platform it shows LES AIM. even when I place a buy order I get the massage im buying AIM company share
oh, that is interesting because I'm using T212, in the platform it shows LES AIM. even when I place a buy order I get the massage im buying AIM company share